About this study
Physician-scientists are studying a new way to treat children and young adults with central nervous system germinoma, a type of brain tumor.
Germinoma treatment usually includes chemotherapy and radiation therapy. This treatment generally effectively cures most of the patients. But radiation therapy to the brain has been linked to certain long-term side effects. These include learning problems and hormonal dysregulation (how the body makes and controls hormones).
ACNS 2321 aims to treat newly diagnosed germinoma patients with lower-dose radiation after chemotherapy. Our goal is to reduce some of the radiation-induced side effects while maintaining survival rates. Patients in this study will get the chemotherapy drugs carboplatin and etoposide to reduce the tumor’s size followed by a lower dose of radiation based on the tumor’s response to chemotherapy.
If the results show that lower-dose radiation is as effective as the standard treatment, it could lead to safer and gentler therapies for children and young adults with germinoma.
Eligibility overview
- Newly diagnosed germinoma
- 3–29 years old